CytoSorbents Corporation received a notice from Nasdaq stating it is not in compliance with the minimum Market Value of Listed Securities requirement, which must be at least $35 million. The company has been granted a 180-day grace period until December 28, 2026, to regain compliance. To satisfy the requirement, the market value of the common stock must meet or exceed $35 million for at least 10 consecutive business days during this period. Management is evaluating actions to restore compliance, including potentially increasing stockholders' equity to at least $2.5 million. Failure to meet the standard by the compliance date may result in delisting. CytoSorbents Corporation is a medical technology company that develops products for extracorporeal blood purification.

CytoSorbents Corporation announced at the 2026 Life Sciences Forum that it has scheduled two pre-submission meetings with the FDA in August 2026 to discuss its ticagrelor and DOAC programs. CytoSorbents Corporation is a life sciences company that develops and commercializes medical devices and pharmaceutical-based products for the treatment of extracorporeal blood purification. extracorporeal blood purification industry.